Biosimilars and Pharmaceutical Companies

STAT+: As Humira biosimilars take over the market, CVS has created a new ploy: the drug ‘rebate credit’

STAT

MARCH 18, 2024

The biggest enticement that large pharmacy benefit managers offer to the employers that hire them is drug rebates — a steady stream of money sent back to their clients, a tangible symbol of the discounts that PBMs are able to wrangle out of pharmaceutical companies.

STAT+: Coherus works with Mark Cuban to sell biosimilar Humira at steep discounts

STAT

JUNE 1, 2023

In a bold move, Coherus BioSciences plans to sell a biosimilar version of Humira — one of the world’s best-selling medicines — at a steep discount, and will work with Mark Cuban’s generic drug company to make the medicine available directly to consumers for even less.

STAT+: Amgen pricing for its Humira biosimilar may benefit PBMs and insurers more than patients

STAT

JANUARY 31, 2023

Underscoring the opaque and confusing nature of pharmaceutical pricing, Amgen announced long-awaited pricing for its biosimilar version of Humira – the world’s best-selling medicine – and the numbers suggest the biggest winners may be health insurers and others in the supply chain, but not patients.

STAT+: Patent thickets and terminal disclaimers: How pharma blocks biosimilars from the marketplace

STAT

DECEMBER 21, 2023

To ring the register, a pharmaceutical company may create a patent thicket , which involves filing dozens of patents that, in some cases, add little value to their medicines but extend precious monopolies. As a result, a drug company can quickly add a number of patents that can be used to protect its medicines from would-be rivals.

STAT+: Lawmakers want FTC to probe big PBMs over private-label biosimilar deals

STAT

OCTOBER 2, 2024

The effort comes after CVS Health and Cigna — which own CVS Caremark and Express Scripts, respectively — launched subsidiaries that are striking “co-manufacturing” deals with companies that make biologic medicines and lower-cost versions known as biosimilars.

Labelling

STAT+: Pharmalittle: Amgen pricing for Humira biosimilar may not help patients; pharma wins court battle over drug discount program

STAT

JANUARY 31, 2023

… Underscoring the opaque and confusing nature of pharmaceutical pricing, Amgen announced long-awaited pricing for its biosimilar version of Humira – the world’s best-selling medicine – and the numbers suggest the biggest winners may be health insurers and others in the supply chain, but not patient s, STAT explains.

Construction starts on $400m biosimilars production centre in Slovenia

European Pharmaceutical Review

DECEMBER 12, 2023

The first stage of construction has officially begun on Lek Pharmaceuticals’ new biologics and biosimilars production centre in Lendava, north eastern Slovenia. Sandoz is the parent company of Lek Pharmaceuticals , the oldest pharmaceutical company in Slovenia.

STAT+: Pharmalittle: We’re reading about a key Merck drug trial, cheap Wegovy in China, and more

STAT

NOVEMBER 19, 2024

Analysts expect that Merck might be able to continue to charge a higher price for the in-office version while competition from biosimilar medicines pushes down the price for Keytruda’s existing formulation.

Boehringer Ingelheim to lay off staff amid biosimilar challenges

BioPharma Dive

APRIL 5, 2024

The German pharmaceutical company is “streamlining” its custom-facing teams behind Cyltezo, a copycat version of AbbVie’s immune disease drug Humira.

Five things to watch as the Biosimilars market heats up in 2022

pharmaphorum

APRIL 1, 2022

Congress and the White House to curtail prescription drug prices, many experts continue to point to biosimilars and their promising potential to usher in competition, increase access, and drive down costs for patients—and the U.S. And already in the first quarter of 2022, the FDA approved a third filgrastim biosimilar, Releuko.

Amgen opens its most advanced manufacturing facility to date

European Pharmaceutical Review

FEBRUARY 27, 2024

Novel biosimilar approval In the same month, the US Food and Drug Administration (FDA) approved Amgen’s Wezlana (ustekinumab-auub) as the first biosimilar to reference blockbuster drug Stelara (ustekinumab).

Ranibizumab biosimilar by Generium for Wet (Neovascular / Exudative) Macular Degeneration: Likelihood of Approval

Pharmaceutical Technology

FEBRUARY 23, 2023

Ranibizumab biosimilar is under clinical development by Generium and currently in Phase III for Wet (Neovascular / Exudative) Macular Degeneration. GlobalData’s report assesses how Ranibizumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Hetero Labs Limited-Walk-In Interviews for Production/ EHS/ Engineering- API On 26th Feb’ 2023

Pharma Pathway

FEBRUARY 23, 2023

Hetero Labs Limited-Walk-In Interviews for Production/ EHS/ Engineering- API On 26th Feb’ 2023 Job Description Hetero Labs Limited is one of India’s generic pharmaceutical companies and the “world’s largest producer of anti- retroviral drugs”. Hetero also offers custom pharmaceutical services to its partners around the world.

Biocon signs licensing and supply pact with Biomm S.A for Semaglutide commercialisation in Brazil

Express Pharma

APRIL 18, 2024

a specialty pharmaceutical company in Brazil, for the commercialisation of its vertically integrated drug product, Semaglutide (gOzempic), which is used to improve glycemic control in adults with type-2 diabetes.

Diabetes

Hetero Limited-Campus Interview for B.Sc / M.Sc -Chemistry/ B.Com/ B.Pharm/ ITI Fitter/ Diploma Mechanical On 9th Jan’ 2023

Pharma Pathway

JANUARY 7, 2023

Hetero Labs Limited is one of India’s generic pharmaceutical companies and the “world’s largest producer of anti- retroviral drugs”. Hetero’s business includes APIs, generic, biosimilars, custom pharmaceutical services, and branded generics.

Biocon signs commercialisation pact with Juno Pharma in Canada for Liraglutide

Express Pharma

OCTOBER 6, 2023

Biocon has signed a partnership agreement with Juno Pharmaceuticals, a specialty pharmaceutical company in Canada, for the commercialisation of its vertically integrated, complex formulation, Liraglutide, a drug-device combination for the treatment and management of Type 2 diabetes and obesity.

Diabetes

Hetero Labs Limited-Walk-In Interviews for Freshers in Production/ QA/ QC/ Maintenance On 5th Mar’ 2023

Pharma Pathway

FEBRUARY 26, 2023

Hetero Labs Limited-Walk-In Interviews for Freshers in Production/ QA/ QC/ Maintenance On 5th Mar’ 2023 Job Description Hetero Labs Limited is one of India’s generic pharmaceutical companies and the “world’s largest producer of anti- retroviral drugs”. Hetero also offers custom pharmaceutical services to its partners around the world.

Hetero Labs Limited-Placement Drive for Freshers in Production/ QA QC/ Engineering On 16th Feb’ 2023

Pharma Pathway

FEBRUARY 14, 2023

Hetero Labs Limited-Placement Drive for Freshers in Production/ QA QC/ Engineering On 16th Feb’ 2023 Job Description Hetero Labs Limited is one of India’s generic pharmaceutical companies and the “world’s largest producer of anti- retroviral drugs”.

Hetero Labs Limited-Walk-In Interviews for Production/ Production Packing/ QA/QC / Engineering On 10th & 11th Dec’ 2022

Pharma Pathway

DECEMBER 3, 2022

Hetero Labs Limited is one of India’s generic pharmaceutical companies and the “world’s largest producer of anti- retroviral drugs”. Hetero’s business includes APIs, generic, biosimilars, custom pharmaceutical services, and branded generics.

Hetero Labs Limited-Walk-In Interviews for Freshers in QA/ QC On 14th Dec’ 2022

Pharma Pathway

DECEMBER 13, 2022

Hetero Labs Limited is one of India’s generic pharmaceutical companies and the “world’s largest producer of anti- retroviral drugs”. Hetero’s business includes APIs, generic, biosimilars, custom pharmaceutical services, and branded generics.

Hetero Labs Limited-Walk-In Interviews for EHS- Process Safety Management/ Process Safety Lab On 24th Sept’ 2022

Pharma Pathway

SEPTEMBER 21, 2022

Hetero Labs Limited is one of India’s generic pharmaceutical companies and the “world’s largest producer of anti- retroviral drugs”. Hetero’s business includes APIs, generic, biosimilars, custom pharmaceutical services, and branded generics.

Hetero Labs Limited-Campus Placement Drive for B.Sc Chemistry/ B.Com Freshers On 14th Feb’ 2023

Pharma Pathway

FEBRUARY 12, 2023

Chemistry/ B.Com Freshers On 14th Feb’ 2023 Job Description Hetero Labs Limited is one of India’s generic pharmaceutical companies and the “world’s largest producer of anti- retroviral drugs”. Hetero’s business includes APIs, generic, biosimilars, custom pharmaceutical services, and branded generics.

Hetero Labs Limited-Campus Placement Drive for Freshers On 17th Sept’ 2022

Pharma Pathway

SEPTEMBER 16, 2022

Hetero Labs Limited is one of India’s generic pharmaceutical companies and the “world’s largest producer of anti- retroviral drugs”. Hetero’s business includes APIs, generic, biosimilars, custom pharmaceutical services, and branded generics.

Hetero Labs Limited-Walk-In Interviews for Freshers & Experienced in Production/Packing/ QA/ Stores On 4th Feb’ 2023

Pharma Pathway

FEBRUARY 3, 2023

Hetero Labs Limited-Walk-In Interviews for Freshers & Experienced in Production/Packing/ QA/ Stores On 4th Feb’ 2023 Job Description Hetero Labs Limited is one of India’s generic pharmaceutical companies and the “world’s largest producer of anti- retroviral drugs”.

Hetero Labs Limited-Walk-In Interviews for Freshers & Experienced in QC -Instrumentation On 4th Mar’ 2023

Pharma Pathway

MARCH 3, 2023

Hetero Labs Limited-Walk-In Interviews for Freshers & Experienced in QC -Instrumentation On 4th Mar’ 2023 Job Description Hetero Labs Limited is one of India’s generic pharmaceutical companies and the “world’s largest producer of anti- retroviral drugs”.

Hetero Limited-Campus Placement Drive for Freshers -Production/ QA/ QC/ R&D On 9th, 13th, 17th, 22nd December 2022

Pharma Pathway

DECEMBER 7, 2022

Hetero Labs Limited is one of India’s generic pharmaceutical companies and the “world’s largest producer of anti- retroviral drugs”. Hetero’s business includes APIs, generic, biosimilars, custom pharmaceutical services, and branded generics.

Hetero Labs Limited-Walk-In Interviews for Freshers in QC/ Production Dept. On 16th Sept’ 2022

Pharma Pathway

SEPTEMBER 13, 2022

Hetero Labs Limited is one of India’s generic pharmaceutical companies and the “world’s largest producer of anti- retroviral drugs”. Hetero’s business includes APIs, generic, biosimilars, custom pharmaceutical services, and branded generics.

Hetero Labs Limited-Walk-In Interviews for Freshers in Quality Control/ Quality Assurance/ Production On 5th Feb’ 2023

Pharma Pathway

FEBRUARY 2, 2023

Hetero Labs Limited-Walk-In Interviews for Freshers in Quality Control/ Quality Assurance/ Production On 5th Feb’ 2023 Job Description Hetero Labs Limited is one of India’s generic pharmaceutical companies and the “world’s largest producer of anti- retroviral drugs”.

Hetero Labs Limited-Walk-In Interviews for QA/ Production On 17th Sept’ 2022

Pharma Pathway

SEPTEMBER 13, 2022

Hetero Labs Limited is one of India’s generic pharmaceutical companies and the “world’s largest producer of anti- retroviral drugs”. Hetero’s business includes APIs, generic, biosimilars, custom pharmaceutical services, and branded generics.

Hetero Labs Limited-Walk-In Interviews for Freshers in Production/ QA/ QC/ Maintenance On 21st Feb’ 2023

Pharma Pathway

FEBRUARY 20, 2023

Hetero Labs Limited-Walk-In Interviews for Freshers in Production/ QA/ QC/ Maintenance On 21st Feb’ 2023 Job Description Hetero Labs Limited is one of India’s generic pharmaceutical companies and the “world’s largest producer of anti- retroviral drugs”.

Hetero Labs Limited-Walk-In Interviews for Production/ Packing/ QC Departments On 10th Dec’ 2022

Pharma Pathway

DECEMBER 8, 2022

Hetero Labs Limited is one of India’s generic pharmaceutical companies and the “world’s largest producer of anti- retroviral drugs”. Hetero’s business includes APIs, generic, biosimilars, custom pharmaceutical services, and branded generics.

STAT+: Pharmalittle: WHO pandemic accord may force pharma to disclose prices; FDA OKs first therapy to delay type 1 diabetes

STAT

NOVEMBER 18, 2022

… Pharmaceutical companies could be made to disclose prices and deals for products they make to fight future global health emergencies, under new rules that would govern a World Health Organization-backed pandemic accord , Reuters reports. Or you may want to take stock of your life. Well, whatever you do, have a grand time.

Diabetes

Handling Drug Patent Invalidity Claims

Drug Patent Watch

DECEMBER 8, 2024

The pharmaceutical industry is heavily reliant on patents to protect intellectual property and maintain market exclusivity. However, with the increasing competition from generic and biosimilar manufacturers, patent invalidity claims have become a significant challenge for pharmaceutical companies.

Hetero Labs Limited-Walk-In Interviews for Freshers in QC/ QA/ R&D/ Production/ HR/ Maintenance On 29th Jan’ 2023

Pharma Pathway

JANUARY 26, 2023

Hetero Labs Limited-Walk-In Interviews for Freshers in QC/ QA/ R&D/ Production/ HR/ Maintenance On 29th Jan’ 2023 Job Description Hetero Labs Limited is one of India’s generic pharmaceutical companies and the “world’s largest producer of anti- retroviral drugs”.

Dr. Reddy’s Laboratories Ltd.-Walk-In Interviews for fresher -Apprentice Trainee On 8th Feb’ 2023

Pharma Pathway

FEBRUARY 4, 2023

is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three business-Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products. Reddy’s Laboratories Ltd.-Walk-In

Hetero Labs Limited-Walk-In Interviews for Quality Control/ Quality Assurance/ Engineering/ Safety -EHS On 29th Jan’ 2023

Pharma Pathway

JANUARY 24, 2023

Hetero Labs Limited-Walk-In Interviews for Quality Control/ Quality Assurance/ Engineering/ Safety -EHS On 29th Jan’ 2023 Job Description Hetero Labs Limited is one of India’s generic pharmaceutical companies and the “world’s largest producer of anti- retroviral drugs”.

Hetero Labs Limited-Walk-In Drive for B.Pharm/ M.Pharm/ M.Sc in Regulatory Affairs On 17th Feb’ 2023

Pharma Pathway

FEBRUARY 16, 2023

in Regulatory Affairs On 17th Feb’ 2023 Job Description Hetero Labs Limited is one of India’s generic pharmaceutical companies and the “world’s largest producer of anti- retroviral drugs”. Hetero’s business includes APIs, generic, biosimilars, custom pharmaceutical services, and branded generics.

Hetero Labs Limited-Walk-In Interviews for AR&D/ FR&D/ Analytical DQA On 28th Jan’ 2023

Pharma Pathway

JANUARY 24, 2023

Hetero Labs Limited-Walk-In Interviews for AR&D/ FR&D/ Analytical DQA On 28th Jan’ 2023 Job Description Hetero Labs Limited is one of India’s generic pharmaceutical companies and the “world’s largest producer of anti- retroviral drugs”. Hetero also offers custom pharmaceutical services to its partners around the world.

Method Validation

Method Validation Biosimilars Pharmaceutical Companies Pharmaceutical Companies

Dr. Reddy’s Laboratories Ltd.-Hiring B.Sc/ M.Sc for Quality Control/ AQA-Formulations Departments -Apply Now

Pharma Pathway

JANUARY 10, 2023

is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three business-Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products. Reddy’s Laboratories Ltd.-Hiring Hiring B.Sc/ M.Sc Job Description.

Hetero Labs Limited-Walk-In Interviews for Freshers in QA/ QC/ Production On 3rd Feb’ 2023

Pharma Pathway

JANUARY 30, 2023

Hetero Labs Limited-Walk-In Interviews for Freshers in QA/ QC/ Production On 3rd Feb’ 2023 Job Description Hetero Labs Limited is one of India’s generic pharmaceutical companies and the “world’s largest producer of anti- retroviral drugs”. Hetero also offers custom pharmaceutical services to its partners around the world.

Osteoporosis treatment options – down to the bare bones

pharmaphorum

OCTOBER 13, 2022

ResearchandMarkets also recently published a report , which highlighted only biosimilars as the emerging treatments for osteoporosis. Emerging research and biosimilars. Sandoz recently announced positive clinical trial results from a phase 1/3 into its biosimilar to denosumab.

Dr. Reddy’s Laboratories Ltd.-Walk-In Drive for Multiple Positions On 8th Jan’ 2023

Pharma Pathway

JANUARY 5, 2023

is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three business-Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products. Company Name: Dr. Reddy’s Laboratories. Reddy’s Laboratories Ltd.-Walk-In

Dr. Reddy’s Laboratories Ltd.-Openings for R&D/ Quality Assurance -Apply Now

Pharma Pathway

SEPTEMBER 13, 2022

is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three business-Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products. Company Name: Dr. Reddy’s Laboratories. Reddy’s Laboratories Ltd.-Openings

Dr. Reddy’s Laboratories Ltd.-Hiring for Freshers in Production QC/ QA Departments -Apply Now

Pharma Pathway

DECEMBER 19, 2022

is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three business-Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products. Reddy’s Laboratories Ltd.-Hiring Job Description. Dr. Reddy’s Laboratories Ltd.

STAT+: As Humira biosimilars take over the market, CVS has created a new ploy: the drug ‘rebate credit’

STAT+: Coherus works with Mark Cuban to sell biosimilar Humira at steep discounts

Trending Sources

STAT+: Amgen pricing for its Humira biosimilar may benefit PBMs and insurers more than patients

STAT+: Patent thickets and terminal disclaimers: How pharma blocks biosimilars from the marketplace

STAT+: Lawmakers want FTC to probe big PBMs over private-label biosimilar deals

STAT+: Pharmalittle: Amgen pricing for Humira biosimilar may not help patients; pharma wins court battle over drug discount program

Construction starts on $400m biosimilars production centre in Slovenia

STAT+: Pharmalittle: We’re reading about a key Merck drug trial, cheap Wegovy in China, and more

Boehringer Ingelheim to lay off staff amid biosimilar challenges

Five things to watch as the Biosimilars market heats up in 2022

Amgen opens its most advanced manufacturing facility to date

Ranibizumab biosimilar by Generium for Wet (Neovascular / Exudative) Macular Degeneration: Likelihood of Approval

Hetero Labs Limited-Walk-In Interviews for Production/ EHS/ Engineering- API On 26th Feb’ 2023

Biocon signs licensing and supply pact with Biomm S.A for Semaglutide commercialisation in Brazil

Hetero Limited-Campus Interview for B.Sc / M.Sc -Chemistry/ B.Com/ B.Pharm/ ITI Fitter/ Diploma Mechanical On 9th Jan’ 2023

Biocon signs commercialisation pact with Juno Pharma in Canada for Liraglutide

Hetero Labs Limited-Walk-In Interviews for Freshers in Production/ QA/ QC/ Maintenance On 5th Mar’ 2023

Hetero Labs Limited-Placement Drive for Freshers in Production/ QA QC/ Engineering On 16th Feb’ 2023

Hetero Labs Limited-Walk-In Interviews for Production/ Production Packing/ QA/QC / Engineering On 10th & 11th Dec’ 2022

Hetero Labs Limited-Walk-In Interviews for Freshers in QA/ QC On 14th Dec’ 2022

Hetero Labs Limited-Walk-In Interviews for EHS- Process Safety Management/ Process Safety Lab On 24th Sept’ 2022

Hetero Labs Limited-Campus Placement Drive for B.Sc Chemistry/ B.Com Freshers On 14th Feb’ 2023

Hetero Labs Limited-Campus Placement Drive for Freshers On 17th Sept’ 2022

Hetero Labs Limited-Walk-In Interviews for Freshers & Experienced in Production/Packing/ QA/ Stores On 4th Feb’ 2023

Hetero Labs Limited-Walk-In Interviews for Freshers & Experienced in QC -Instrumentation On 4th Mar’ 2023

Hetero Limited-Campus Placement Drive for Freshers -Production/ QA/ QC/ R&D On 9th, 13th, 17th, 22nd December 2022

Hetero Labs Limited-Walk-In Interviews for Freshers in QC/ Production Dept. On 16th Sept’ 2022

Hetero Labs Limited-Walk-In Interviews for Freshers in Quality Control/ Quality Assurance/ Production On 5th Feb’ 2023

Hetero Labs Limited-Walk-In Interviews for QA/ Production On 17th Sept’ 2022

Hetero Labs Limited-Walk-In Interviews for Freshers in Production/ QA/ QC/ Maintenance On 21st Feb’ 2023

Hetero Labs Limited-Walk-In Interviews for Production/ Packing/ QC Departments On 10th Dec’ 2022

STAT+: Pharmalittle: WHO pandemic accord may force pharma to disclose prices; FDA OKs first therapy to delay type 1 diabetes

Handling Drug Patent Invalidity Claims

Hetero Labs Limited-Walk-In Interviews for Freshers in QC/ QA/ R&D/ Production/ HR/ Maintenance On 29th Jan’ 2023

Dr. Reddy’s Laboratories Ltd.-Walk-In Interviews for fresher -Apprentice Trainee On 8th Feb’ 2023

Hetero Labs Limited-Walk-In Interviews for Quality Control/ Quality Assurance/ Engineering/ Safety -EHS On 29th Jan’ 2023

Hetero Labs Limited-Walk-In Drive for B.Pharm/ M.Pharm/ M.Sc in Regulatory Affairs On 17th Feb’ 2023

Hetero Labs Limited-Walk-In Interviews for AR&D/ FR&D/ Analytical DQA On 28th Jan’ 2023

Dr. Reddy’s Laboratories Ltd.-Hiring B.Sc/ M.Sc for Quality Control/ AQA-Formulations Departments -Apply Now

Hetero Labs Limited-Walk-In Interviews for Freshers in QA/ QC/ Production On 3rd Feb’ 2023

Osteoporosis treatment options – down to the bare bones

Dr. Reddy’s Laboratories Ltd.-Walk-In Drive for Multiple Positions On 8th Jan’ 2023

Dr. Reddy’s Laboratories Ltd.-Openings for R&D/ Quality Assurance -Apply Now

Dr. Reddy’s Laboratories Ltd.-Hiring for Freshers in Production QC/ QA Departments -Apply Now

Stay Connected